Philips has introduced its VeriSight Pro 3D intracardiac echocardiography (ICE) catheter to the European market. The device provides real-time 3D imaging inside the heart, helping physicians perform complex procedures with enhanced clarity — without the need for general anesthesia.
The catheter, equipped with a miniaturized ultrasound probe approximately 3 mm in diameter, navigates through blood vessels into heart chambers. It delivers high-quality 2D and 3D images to assist in planning and guiding interventions such as transcatheter valve repair and left atrial appendage closure by visualizing challenging structures like the tricuspid valve.
Philips first reported U.S. use in 2021, with positive clinical data from the Mayo Clinic in 2023. The launch in Europe marks a key milestone for broader adoption of this minimally invasive imaging technology.
Stacy Beske, Philips’ business leader for Image-Guided Therapy Devices, said:
“VeriSight Pro reflects our commitment to innovations that enhance precision, reduce procedural complexity, and improve patient care. Its availability in Europe supports care teams with integrated solutions tailored to their workflows.”
Follow MEDWIRE.AI for updates on innovative cardiovascular imaging technologies.
